(Reuters) -Institutional Shareholder Services has recommended Pfizer investors reject a proposal on executive compensation ...

In a report released today, Geoff Meacham from Citi maintained a Hold rating on Pfizer (PFE – Research Report), with a price target of $27.00.

Pfizer’s (PFE) stock has fallen ill since the COVID-19 pandemic waned, and it is still experiencing some aftereffects. The ...

When Wall Street analysts decide to come out of their caves and boost a certain stock, retail investors should pay attention ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $152.57, a high ...

Pfizer’s stock has underperformed lately, falling 4.6% while still doing marginally better than its peers. Analysts have made ...

Eastern time, the S&P 500 was down 0.8 per cent, the Dow Jones Industrial Average was down 0.3 per cent, and the Nasdaq ...

US indices retreat on tariff worries as VIX jumps to 22.44. Nvidia drops 3.9%, Microsoft falls 2.2%, while defensive sectors ...

While tariffs have triggered market volatility, certain pharmaceutical stocks still present strong investment opportunities.

A portfolio composed of Ultra SWAN stocks can deliver strong returns for investors. Read about six stock selections that can ...

Better than expected commodity performance tends to make the bottom line look better when prices stay high, even though that ...

HONG KONG (AP) — Asian shares were mixed Monday after gains in technology stocks snapped Wall Street’s four-week losing ...